These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1316076)

  • 21. Pharmacokinetics of lomefloxacin in patients with cirrhosis.
    Lebrec D; Gaudin C; Benhamou JP
    Am J Med; 1992 Apr; 92(4A):41S-44S. PubMed ID: 1316069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacokinetic disposition of fluoroquinolones in the lung.
    Wise R; Baldwin DR; Andrews JM; Honeybourne D
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():65-71. PubMed ID: 1664831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The penetration of rufloxacin into sites of potential infection in the respiratory tract.
    Wise R; Andrews J; Imbimbo BP; Greaves I; Honeybourne D
    J Antimicrob Chemother; 1993 Dec; 32(6):861-6. PubMed ID: 8144426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prostatic tissue and fluid levels of lomefloxacin (NY-198)].
    Nasu Y; Nishitani Y; Yamada D; Hayata S; Tsugawa M; Kishi M; Mizuno A; Kumon H; Ohmori H; Nanba K
    Hinyokika Kiyo; 1989 Mar; 35(3):551-6. PubMed ID: 2735259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues.
    Wise R
    Am J Med; 1991 Dec; 91(6A):67S-70S. PubMed ID: 1662897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibacterial activity of lomefloxacin in the urine during the 4 days following a single 400 mg oral dose].
    Guibert J; Kitzis MD; Acar JF; Masquelier AM; Bellanger B
    Pathol Biol (Paris); 1989 May; 37(5):411-4. PubMed ID: 2506515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lemofloxacin: antimicrobial ability and clinico-pharmacokinetic basis for use in urogenital infections].
    Iakovlev SV
    Urologiia; 2002; (1):11-4. PubMed ID: 11877963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
    Kovarik JM; Hoepelman AI; Smit JM; Sips PA; Rozenberg-Arska M; Glerum JH; Verhoef J
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2458-61. PubMed ID: 1336948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and safety of single oral doses of lomefloxacin.
    Morse IS
    Biopharm Drug Dispos; 1990; 11(6):543-51. PubMed ID: 2207304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxazole.
    Guibert J; Capron MH
    J Int Med Res; 1992 Nov; 20(6):467-74. PubMed ID: 1337525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal clearance of lomefloxacin is decreased by furosemide.
    Sudoh T; Fujimura A; Shiga T; Sasaki M; Harada K; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1994; 46(3):267-9. PubMed ID: 8070509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposable 1-day Acuvue contact lenses for the delivery of lomefloxacin to rabbits' eyes.
    Tian X; Iwatsu M; Kanai A
    CLAO J; 2001 Oct; 27(4):212-5. PubMed ID: 11725984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg.
    Cowling P; Rogers S; McMullin CM; White LO; Lovering AM; MacGowan AP; Reeves DS
    J Antimicrob Chemother; 1991 Jul; 28(1):101-7. PubMed ID: 1663107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.
    Mattina R; Bonfiglio G; Cocuzza CE; Gulisano G; Cesana M; Imbimbo BP
    Chemotherapy; 1991; 37(6):389-97. PubMed ID: 1662127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraprostatic distribution of lomefloxacin following multiple-dose administration.
    Kovarik JM; de Hond JA; Hoepelman IM; Boon T; Verhoef J
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2398-401. PubMed ID: 2088193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%.
    Tabbara KF; El-Sheikh HF; Islam SM; Hammouda E
    Eur J Ophthalmol; 1999; 9(4):269-75. PubMed ID: 10651190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular distribution of lomefloxacin 0.3% after a single instillation in the infected eye of pigmented rabbits.
    Elena PP; Jauch A
    J Ocul Pharmacol Ther; 1997 Dec; 13(6):551-8. PubMed ID: 9436158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.
    Morrison PJ; Mant TG; Norman GT; Robinson J; Kunka RL
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1503-7. PubMed ID: 3214495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penetration of ampicillin into human bronchial secretions.
    Bergogne-Berezin E; Berthelot G; Kafe H; Morel C
    Infection; 1979; 7 Suppl 5():S463-4. PubMed ID: 511358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the safety and efficacy of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infections: results from a multicenter study.
    Andrade-Villanueva J; Flores-Gaxiola A; Lopez-Guillen P; Aguirre-Avalos G; Morfin-Otero R; Rodriguez-Noriega E
    Am J Med; 1992 Apr; 92(4A):71S-74S. PubMed ID: 1316074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.